- Home
- NGNE
NGNE
Neurogene Inc.
as 06-30-2025 1:32pm EST
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 251.9M | IPO Year: | N/A |
| Target Price: | $41.86 | AVG Volume (30 days): | 193.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.88 - $74.49 | Next Earning Date: | 08-08-2025 |
| Revenue: | $925,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Neurogene Inc. (NGNE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cobb Stuart | NGNE | Chief Scientific Officer | May 14 '25 | Sell | $15.15 | 6,797 | $103,003.10 | 20,794 |
Latest Neurogene Inc. News
NGNE Breaking Stock News: Dive into NGNE Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 days ago
Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth
TipRanks
13 days ago
Craig-Hallum bullish on Neurogene, initiates with a Buy
Business Wire
24 days ago
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
a month ago
Short Report: Bears bite into Krispy Kreme after another weak earnings report
Business Wire
a month ago
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
Business Wire
2 months ago
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
Business Wire
2 months ago
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
2 months ago
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
Compare NGNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NGNE Neurogene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.